Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SpectRx has entered into a manufacturing agreement with the MacKay Group to supply non-invasive breast and cervical cancer detection products for certain territories within the Asian market.
Subscribe to our email newsletter
Under the terms of the agreement, SpectRx plans to contract manufacture for MacKay 1,000 Biofield breast diagnostic systems, and MacKay plans to purchase a specified minimum number of SpectRx’s LightTouch non-invasive cervical cancer detection devices and associated single-patient-use disposables. Production of the Biofield system is expected to commence in the first half of 2008, with production of the LightTouch device to follow.
The SpectRx LightTouch Non-invasive Cervical Cancer Detection Device uses proprietary technology to identify cancers and precancers painlessly and non-invasively by scanning the cervix with light. The technology distinguishes between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level.
Mark Faupel, CEO and president of SpectRx, said: “This agreement with the MacKay Group should enable us to ramp up our manufacturing facility and provide early access to the rapidly growing Asian healthcare markets for our core cervical cancer detection technology.”